Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 6Phase 1/2 4Phase 3 2Phase 2/3 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Gastrointestinal 1

Conditions

Multiple Myeloma 1Gastrointestinal Stromal Tumors 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × tanespimycin × Clear all
NCT00688766 2012-12-11

Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib

Infinity Pharmaceuticals, Inc.

Phase 3 Terminated
47 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00546780 2011-06-28

BMS TIME-1

Bristol-Myers Squibb

Phase 3 Completed
31 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡